IM Cannabis Corp. reports developments tied to its medical cannabis platform serving patients in Israel and Germany. Company updates commonly address medical cannabis operations, regulatory and commercial positioning, operating and financial results, and the management of liquidity through note purchase agreements, convertible notes and common share purchase warrants.
Recurring IMCC news also includes Nasdaq listing-compliance notices, board and executive appointments, shareholder or governance matters, and disclosures related to material agreements and capital structure. The company’s announcements frame IM Cannabis as an international medical cannabis issuer with cross-border supply and compliance considerations in regulated cannabis markets.
IM Cannabis (IMCC) completed its sale of IMC Holdings to Slil, with a previously paid C$3 million forming part of the consideration. IM Cannabis retained its Israeli operations through a pre-closing reorganization. IMC Holdings held interests in Adjupharm, Xinteza API and Shiran, and its remaining liabilities continue as its obligations under Slil's ownership. Those liabilities were capped at C$9.4 million under the agreement, subject to mutual adjustment; the cap excludes the subsidiaries' direct liabilities.
Based on unaudited pro forma analysis, IM Cannabis expects an approximately C$3 million improvement in shareholders' equity, although the actual accounting impact may differ. It also expects improved working capital and reduced consolidated liabilities associated with IMC Holdings. Slil is controlled by CEO Oren Shuster. Citing serious financial difficulty, the company used exemptions from formal valuation and minority approval requirements.
IM Cannabis (IMCC) closed a registered direct offering on September 24, 2026, raising US$1.31 million in gross proceeds. It issued 655,000 common shares at US$2.00 each; gross proceeds are before offering expenses. The company intends to use net proceeds for working capital and general corporate purposes, potentially including the evaluation of other business opportunities.
Director-affiliated Invest-Pro subscribed for 164,585 shares for US$329,170 at the same price. The company relied on financial-hardship exemptions from formal valuation and minority shareholder approval requirements for this related-party transaction. Its board and at least two-thirds of its independent directors determined that the company was in serious financial difficulty, that the offering was designed to improve its financial position, and that its terms were reasonable in the circumstances. All directors independent with respect to the offering approved it.
IM Cannabis (IMCC) regained compliance with Nasdaq’s $1.00 minimum bid price rule on September 23, 2026, closing its bid price deficiency matter.
Nasdaq issued written notice after the closing bid price of the company’s ordinary shares was at least $1.00 per share for 18 consecutive business days, from August 27 through September 22, 2026. The company currently operates in Israel and Germany. If pending transactions announced on August 17, 2026, are completed, IM Cannabis expects to retain its Israeli medical cannabis operations and sell its German operations.
IM Cannabis (IMCC) entered securities purchase agreements for a registered direct offering of 655,000 common shares at US$2.00 per share, for expected gross proceeds of about US$1.31 million before expenses. Closing is expected on or about September 24, 2026, subject to customary conditions.
The company plans to use net proceeds for working capital and general corporate purposes, which may include evaluating additional business opportunities. The offering is made under an effective shelf registration statement on Form F-3 declared effective by the SEC on July 9, 2025, and will be offered only by means of a prospectus supplement and accompanying prospectus filed with the SEC.
One or more purchasers may be a related party under MI 61-101, and the company intends to rely on financial hardship exemptions from formal valuation and minority shareholder approval, based on board and independent director determinations that the company is in serious financial difficulty and that the offering terms are reasonable and designed to improve its financial position.
IM Cannabis (IMCC) signed a non-binding LOI to acquire 51% of Poland-based Space Defense Innovations (SDI), which operates in the European unmanned aerial systems (UAS) market.
SDI, via subsidiary BlueAero Group, distributes and is expected, subject to licenses, to manufacture BlueBird Aero Systems’ tactical UAS and Hybrid Fixed-Wing VTOL-UAS products in Europe with exclusivity in Poland. IMCC plans to pay using common shares and/or pre-funded warrants, capped so no SDI shareholder exceeds 19.99% IMCC ownership, plus a 24‑month seller loan at 9% interest with 100% warrant coverage exercisable at a 25% premium to the signing-day closing price. IMCC will provide SDI an on-demand credit line of up to EUR 2.3 million, convertible into SDI shares at fair market value, subject to a minimum US$5 million valuation.
IMCC obtains a five‑year call option to buy the remaining SDI shares and the right to appoint a board majority. Closing depends on due diligence, definitive agreements and required approvals, and is not assured.
IM Cannabis (IMCC) closed a US$225,000 gross proceeds convertible note financing in a private placement with an institutional lender on September 2, 2026.
The note carries a principal amount of US$225,000 with a 10% original issue discount and bears interest at 8% per annum, rising to 14% if an event of default occurs. It is not repayable in cash and will be settled solely through issuance of common shares upon conversion.
The conversion price is the lower of a fixed US$3.328 per share or 90% of the lowest daily VWAP over the 20 trading days before conversion, subject to a US$0.665692 floor and a 4.99% beneficial ownership cap. IM Cannabis also issued warrants to purchase up to 77,855 common shares at C$4.63 per share, exercisable immediately until September 2, 2031. Net proceeds are intended for general corporate purposes, and the company plans to file a resale registration statement on Form F-3 with the SEC and reserve sufficient shares for conversions and warrant exercises.
IM Cannabis (Nasdaq: IMCC) announced that, effective August 27, 2026, its common shares began trading on Nasdaq on a 30:1 post-consolidated basis. The trading symbol remains IMCC, while the new CUSIP and ISIN are 44969Q505 and CA44969Q5059, respectively.
According to IM Cannabis, the share consolidation reduced outstanding common shares from 18,567,650 to 618,899, subject to rounding. No fractional shares were issued; fractions of at least one-half share were rounded up, and smaller fractions were cancelled. Exercise and conversion terms of outstanding convertible securities were proportionately adjusted. Computershare mailed instructions to registered holders for exchanging pre-consolidation certificates, while beneficial holders do not need to take action and should consult their intermediaries with any questions.
IM Cannabis (Nasdaq: IMCC) has approved a 30-for-1 consolidation of its issued and outstanding common shares (the “Consolidation”). One post-consolidated share will be issued for every thirty pre-consolidated shares. The Board expects the effective date to be August 27, 2026, with authority to effect it on or before September 15, 2026.
According to IM Cannabis, post-Consolidation shares are expected to be reduced from 18,117,650 to approximately 603,922, subject to rounding. No fractional shares will be issued; fractions of at least one-half will be rounded up, others cancelled. The new CUSIP and ISIN will be 44969Q505 and CA44969Q5059. The company states the primary purpose is to increase the per-share trading price to support regaining compliance with Nasdaq’s US$1.00 minimum bid price requirement, for which IM Cannabis has until October 6, 2026, though it cautions there is no assurance the action will restore compliance.
IM Cannabis (Nasdaq: IMCC) entered into a definitive share purchase agreement on August 16, 2026 to sell all shares of I.M.C. Holdings to Slil.com Holding. Before closing, IMC Holdings will be reorganized so that IM Cannabis retains its Israeli medical cannabis operations.
Following the reorganization, IMC Holdings will mainly hold equity in Adjupharm GmbH, Xinteza API and Shiran, plus certain retained liabilities to be assumed by Slil. Consideration consists of prior C$3,000,000 advance payments and Slil’s assumption of retained liabilities, which are not expected to exceed C$9,400,000 without mutual adjustment. IM Cannabis expects an approximately C$3 million improvement in shareholders’ equity, reduced liabilities and a streamlined structure, with closing targeted by September 30, 2026, subject to customary approvals and Israeli tax clearance.
IM Cannabis (Nasdaq: IMCC) reported weaker results for the three and six months ended June 30, 2026. Six‑month revenue was $16.3 million, down from $25.2 million in 2025, with gross profit falling to $2.9 million from $6.9 million. Six‑month operating loss widened to $3.8 million versus $0.2 million, and net loss increased to $6.9 million (basic and diluted loss of $0.85 per share) compared with a near break‑even loss of $0.02 million in 2025.
For Q2 2026, revenue was $7.6 million (vs. $12.7 million), gross profit $1.5 million (vs. $3.4 million), operating loss $2.1 million (vs. $0.4 million) and net loss $4.4 million or $0.47 per share (vs. $0.2 million or $0.09 per share). As of June 30, 2026, cash was $1.6 million, total assets $24.7 million, total liabilities $30.3 million, and shareholders’ deficit attributable to the company was $5.5 million.